25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

      Clinical cancer research : an official journal of the American Association for Cancer Research

      Carcinoma, Non-Small-Cell Lung, drug therapy, genetics, Cell Line, DNA Copy Number Variations, Disease Progression, Drug Resistance, Neoplasm, Humans, Lung Neoplasms, Models, Molecular, Mutation, Oncogene Proteins, Fusion, Protein Kinase Inhibitors, pharmacology, therapeutic use, Protein Structure, Tertiary, Proto-Oncogene Proteins, Pyrazoles, Pyridines, Receptor Protein-Tyrosine Kinases, chemistry, Receptor, Epidermal Growth Factor, Translocation, Genetic, ras Proteins

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small-molecule ALK inhibitor. Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those who do respond. This study aimed to define molecular mechanisms of resistance to crizotinib in patients with ALK(+) non-small cell lung cancer (NSCLC). We analyzed tissue obtained from 14 patients with ALK(+) NSCLC showing evidence of radiologic progression while on crizotinib to define mechanisms of intrinsic and acquired resistance to crizotinib. Eleven patients had material evaluable for molecular analysis. Four patients (36%) developed secondary mutations in the tyrosine kinase domain of ALK. A novel mutation in the ALK domain, encoding a G1269A amino acid substitution that confers resistance to crizotinib in vitro, was identified in two of these cases. Two patients, one with a resistance mutation, exhibited new onset ALK copy number gain (CNG). One patient showed outgrowth of epidermal growth factor receptor (EGFR) mutant NSCLC without evidence of a persistent ALK gene rearrangement. Two patients exhibited a KRAS mutation, one of which occurred without evidence of a persisting ALK gene rearrangement. One patient showed the emergence of an ALK gene fusion-negative tumor compared with the baseline sample but with no identifiable alternate driver. Two patients retained ALK positivity with no identifiable resistance mechanism. Crizotinib resistance in ALK(+) NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of separate oncogenic drivers.

          Related collections

          Author and article information

          Journal
          22235099
          3311875
          10.1158/1078-0432.CCR-11-2906

          Comments

          Comment on this article